Sigachi Industries Limited SIGACHI NSEPHARMA
Sigachi Industries Limited manufactures and sells microcrystalline cellulose and cellulose powder in India. The company offers cellulose-based products under the HiCel, AceCel, CoatCel, GloCel, and BARETab names; and various chemicals, including colloidal silicon dioxide, carboxy cellulose sodium and mannitol, etc. to active pharmaceutical ingredients, food and nutrition, cosmetic, and chemical industries. It also provides operations and maintenance services in the fields of speciality chemicals, petrochemicals, water treatment, and pharmaceuticals. In addition, the company exports its products. Sigachi Industries Limited was incorporated in 1989 and is headquartered in Hyderabad, India.
READ MORE ›Market & Price
Valuation
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Growth (CAGR)
PROS
- Compounding revenue at 16.5% over 5 years.
- Generates positive free cash flow.
CONS
- Earnings shrank at -95.9% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP ₹ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SIGACHI Sigachi Industries Limited NSEPHARMA | 20.63 | - | ₹789.07 Cr | 0.48% | -12.93% | -14.50% | 16.52% | -95.93% |
| 2 | SUNPHARMA Sun Pharmaceutical Industries Limited NIFTY50NSEAIPHARMA | 1,794.20 | 37.47 | ₹4.30 L Cr | 0.92% | 17.94% | 14.72% | 10.39% | 10.65% |
| 3 | DIVISLAB Divi's Laboratories Limited NSEPHARMA | 6,655.50 | 68.67 | ₹1.77 L Cr | 0.45% | 18.96% | 16.19% | 11.27% | 12.08% |
| 4 | TORNTPHARM Torrent Pharmaceuticals Limited NSEPHARMA | 4,572.20 | 71.63 | ₹1.55 L Cr | 0.85% | 9.05% | 16.99% | 13.27% | 20.22% |
| 5 | APOLLOHOSP Apollo Hospitals Enterprise Limited NIFTY50NSEAIPHARMA | 8,493.00 | 62.93 | ₹1.22 L Cr | 0.24% | 19.79% | 21.50% | 15.33% | 33.34% |
| 6 | CIPLA Cipla Limited NIFTY50NSEAIPHARMA | 1,383.30 | 28.78 | ₹1.12 L Cr | 0.94% | 14.86% | 11.74% | 7.23% | 11.45% |
| 7 | ZYDUSLIFE Zydus Lifesciences Limited NSEPHARMA | 1,105.90 | 22.08 | ₹1.11 L Cr | 0.09% | 19.24% | 18.32% | 16.55% | 36.99% |
| 8 | DRREDDY Dr. Reddy's Laboratories Limited NIFTY50NSEAIPHARMA | 1,276.00 | 24.83 | ₹1.06 L Cr | 0.63% | 14.22% | 11.83% | 10.96% | -1.67% |
| 9 | LUPIN Lupin Limited NIFTY_MIDNSEPHARMA | 2,273.30 | 19.53 | ₹1.04 L Cr | 0.53% | 28.42% | 26.91% | 19.10% | 131.46% |
Quarterly Results
Figures in INR.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 139.42 Cr | 128.20 Cr | 128.25 Cr | 117.21 Cr | 121.90 Cr |
| Cost of Revenue | 64.75 Cr | 50.97 Cr | 62.80 Cr | 65.24 Cr | 59.37 Cr |
| Gross Profit | 74.67 Cr | 77.24 Cr | 65.45 Cr | 51.97 Cr | 62.52 Cr |
| Operating Expenses | 46.16 Cr | 53.43 Cr | 46.07 Cr | 50.43 Cr | 50.69 Cr |
| Operating Income | 28.51 Cr | 23.81 Cr | 19.38 Cr | 1.53 Cr | 11.84 Cr |
| EBITDA | 35.19 Cr | 30.75 Cr | -92.96 Cr | 5.45 Cr | 16.62 Cr |
| Interest Expense | 3.82 Cr | 3.33 Cr | 3.31 Cr | 3.13 Cr | 4.33 Cr |
| Pretax Income | 26.71 Cr | 22.67 Cr | -100.99 Cr | -1.85 Cr | 7.71 Cr |
| Tax Provision | 6.19 Cr | 6.50 Cr | -2.21 L | -1.84 Cr | 6.48 L |
| Net Income | 21.35 Cr | 13.27 Cr | -100.35 Cr | 19.70 L | 7.71 Cr |
| Diluted EPS | 0.52 | 0.39 | -2.63 | 0.01 | 0.20 |
Profit & Loss (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | - | 302.05 Cr | 398.96 Cr | 488.24 Cr | 477.83 Cr |
| Cost of Revenue | - | 162.03 Cr | 224.64 Cr | 222.13 Cr | 247.72 Cr |
| Gross Profit | - | 140.02 Cr | 174.32 Cr | 266.11 Cr | 230.11 Cr |
| Operating Expenses | - | 87.42 Cr | 108.31 Cr | 181.90 Cr | 193.94 Cr |
| Operating Income | - | 52.60 Cr | 66.01 Cr | 84.21 Cr | 36.17 Cr |
| EBITDA | - | 64.20 Cr | 85.83 Cr | 120.51 Cr | -56.21 Cr |
| Interest Expense | - | 3.09 Cr | 5.26 Cr | 12.41 Cr | 13.90 Cr |
| Pretax Income | - | 54.48 Cr | 69.77 Cr | 92.32 Cr | -87.70 Cr |
| Tax Provision | - | 10.94 Cr | 12.51 Cr | 21.86 Cr | -4.89 Cr |
| Net Income | - | 43.54 Cr | 57.18 Cr | 69.56 Cr | -81.76 Cr |
| Diluted EPS | 1.54 | 1.42 | 1.54 | 2.06 | - |
Compounded Sales Growth
| 5 Years: | 16.52% |
| 1 Year: | 1.00% |
Compounded Profit Growth
| 5 Years: | -95.93% |
| 1 Year: | -44.00% |
Stock Price Performance
| 1 Year: | -2.27% |
| 6 Months: | - |
| 3 Months: | - |
| 1 Month: | - |
Balance Sheet (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Total Assets | - | 373.75 Cr | 694.16 Cr | 846.21 Cr | 841.17 Cr |
| Current Assets | - | 177.41 Cr | 313.26 Cr | 394.33 Cr | 389.35 Cr |
| Cash & Equivalents | - | 13.75 Cr | 17.40 Cr | 17.26 Cr | 20.90 Cr |
| Inventory | - | 46.60 Cr | 70.72 Cr | 94.27 Cr | 73.59 Cr |
| Receivables | - | 80.17 Cr | 150.04 Cr | 183.67 Cr | 224.20 Cr |
| Total Liabilities | - | 105.39 Cr | 253.13 Cr | 233.13 Cr | 312.29 Cr |
| Current Liabilities | - | 74.63 Cr | 187.82 Cr | 185.12 Cr | 270.47 Cr |
| Long Term Debt | - | 1.01 Cr | 26.58 Cr | 0 | 0 |
| Total Debt | - | 68.48 Cr | 151.07 Cr | 142.31 Cr | 162.26 Cr |
| Total Equity | - | 268.36 Cr | 429.64 Cr | 600.85 Cr | 521.72 Cr |
| Shares Outstanding | - | 30.74 Cr | 32.82 Cr | 38.21 Cr | 38.21 Cr |
Cash Flows (Annual)
Figures in INR.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 29.02 Cr | 12.89 Cr | 26.93 Cr | 4.30 Cr |
| Investing Cash Flow | - | -91.85 Cr | -160.74 Cr | -93.07 Cr | -52.55 Cr |
| Financing Cash Flow | - | 26.21 Cr | 172.10 Cr | 81.10 Cr | 2.24 Cr |
| Capital Expenditure | - | -100.72 Cr | -85.19 Cr | -43.33 Cr | -41.17 Cr |
| Free Cash Flow | - | -71.70 Cr | -72.30 Cr | -16.40 Cr | -36.86 Cr |
| Net Change in Cash | - | -36.63 Cr | 24.25 Cr | 14.96 Cr | -46.01 Cr |
Ratios (Annual)
Figures in %.
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Gross Margin % | - | 46.4% | 43.7% | 54.5% | 48.2% |
| Operating Margin % | - | 17.4% | 16.5% | 17.2% | 7.6% |
| Net Margin % | - | 14.4% | 14.3% | 14.2% | -17.1% |
| ROE % | - | 16.2% | 13.3% | 11.6% | -15.7% |
| ROCE % | - | 17.6% | 13.0% | 12.7% | 6.3% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SIGACHI